Skip to main content
logo
Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.220
-0.020 (-1.61%)
Sep 28, 2026, 2:12 PM EDT - Market open

Cardiff Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.510.590.680.490.390.36
Revenue Growth
-6.79%-13.18%39.96%26.42%7.52%-1.91%
Cost of Revenue
35.3335.3336.8532.8627.1117.38
Gross Profit
-34.82-34.74-36.17-32.37-26.72-17.02
Selling, General & Admin
16.8214.2212.4813.0413.1811.84
Operating Expenses
7.4514.2212.4813.0413.1811.84
Operating Income
-42.27-48.96-48.65-45.41-39.9-28.86
Interest & Investment Income
2.223.13.264.071.580.26
Other Non Operating Income (Expenses)
-00.01-0.04-0.1-0.380.3
EBT Excluding Unusual Items
-40.05-45.85-45.43-41.44-38.7-28.29
Pretax Income
-40.05-45.85-45.43-41.44-38.7-28.29
Net Income
-40.05-45.85-45.43-41.44-38.7-28.29
Preferred Dividends & Other Adjustments
0.030.030.020.020.020.02
Net Income to Common
-40.08-45.88-45.46-41.47-38.73-28.32
Net Income Growth
------
Shares Outstanding (Basic)
686748454439
Shares Outstanding (Diluted)
686748454439
Shares Change
15.77%40.27%6.65%2.47%11.71%86.97%
EPS (Basic)
-0.59-0.69-0.95-0.93-0.89-0.73
EPS (Diluted)
-0.59-0.69-0.95-0.93-0.89-0.73
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-40.92-37.97-37.77-31.47-34.83-23.25
Free Cash Flow Per Share
-0.60-0.57-0.79-0.70-0.80-0.60
Operating Margin
-8320.08%-8256.32%-7123.13%-9305.74%-10337.31%-8037.60%
Profit Margin
-7888.98%-7736.26%-6655.20%-8496.93%-10033.16%-7887.19%
Free Cash Flow Margin
-8054.33%-6402.53%-5530.45%-6448.57%-9022.28%-6474.93%
EBITDA
-41.92-48.6-48.25-45.01-39.67-28.4
D&A For EBITDA
0.350.360.40.40.240.45
EBIT
-42.27-48.96-48.65-45.41-39.9-28.86
SEC Filings: 10-K · 10-Q